**INTRODUCTION**

Graham-Little Piccardi Lassueur Syndrome (GLPLS) is a rare variant of lichen planopilaris (LPP) characterized by the triad of fibrosing alopecia of the scalp, non-fibrosing alopecia of the axilla and groin, and a follicular spinous papule over the body. It is more common in old age and in postmenopausal females, with only a very few reported cases in the literature wherein the disease has affected males in younger age. In our case, we report a young male who presented with features of cicatricial alopecia of the scalp, non-cicatricial alopecia of the pubic region and axilla, and a follicular spinous papule over the body.
Trichoscopic examination showed peripilar casts over the scalp (Figure 2B), eyebrows, beard, limbs hairs, and loss of follicular openings over scalp. Skin biopsy was taken from follicular papule over right leg showed orthokeratosis, hypergranulosis, acanthosis, and lichenoid infiltrate with necrotic keratinocytes (Figure 5). Mucous membrane examination was unremarkable, and patient has no family history of similar presentation. Based on the clinical and histopathological features, a diagnosis of (GLPLS) was made.

3 | DISCUSSION

Graham-Little-Piccardi-Lassueur syndrome GLPLS was first described by Piccardi in 1913. A second case was then described by Graham-Little in 1915 in a patient referred by Lassueur, resulting in the name it bears today.3 Around 50 cases of GLPLS have been reported since then.4 The condition presents most commonly in middle-aged white women and is characterized by a triad of cicatricial alopecia of the scalp, non-scarring alopecia of the axillae and/or groin, and a follicular papule over body. Its cause remains unknown, but more likely is a T cell–mediated autoimmune condition.4 Recent studies showed that there is decrease expression of peroxisome proliferator-activated receptor (PPAR) and many patients respond well to PPARγ agonists.5 Also, interferon and JAK singling are upregulated in LPP.6

The goal of treatment in GLPLS as well as in other scarring alopecia is to prevent progression of hair loss; thus, early diagnosis and intervention are crucial.1 Many treatment modalities have been used in treating lichen...
planopilaris with variable results. Treatment options range from topical and intralesional steroid to systemic treatment such as hydroxychloroquine, cyclosporine, and pioglitazone.\textsuperscript{7} Baibergenova and Walsh\textsuperscript{8} used PPAR\textgreek{y} agonists (Pioglitazone) which induced complete remission in 25\% and significantly improved symptoms in 50\% of patient diagnosed to have LPP. Pioglitazone side effects are very mild including calf pain, lightheadedness, nausea, dizziness, and hives which were experienced by less than 5\% of patients.\textsuperscript{8} Chiang et al.\textsuperscript{9} studied the use of hydroxychloroquine in the treatment of LPP in 40 patients for 12 months. Their results showed that hydroxychloroquine was very effective in terms of controlling symptoms and halting disease progression with a 69\% and 83\% significant reduction in severity of LPP at both 6 and 12 months, respectively. Treatment with oral tofacitinib either as monotherapy or as adjuvant to other treatment showed measurable 80\% improvement clinically.\textsuperscript{6} Excimer laser (308-nm) was used by Navarini et al. twice weekly in 13 patients and all patient experienced relief of pruritus with 40\% reduction in inflammation but only 25\% of patients had hair regrowth.\textsuperscript{10} Finally, naltrexone was used and showed improvement mainly in term of relieving symptoms such as pruritus.\textsuperscript{11} Our patient was started on hydroxychloroquine after he was evaluated by ophthalmology, and there was no contraindication to start the medication. In addition, the patient was started on topical treatment in the form of tretinoin 0.05\% cream targeting follicular keratotic papules. On follow-up, the patient reported improvement in term of pruritis and reduction on the severity of follicular keratotic papules.

4 | CONCLUSION

GLPLS is a rare variant of LPP characterized by the triad of patchy fibrosing alopecia of the scalp, non-fibrosing alopecia of the axilla and groin, and a follicular spinous papule on the body. The exact cause still unknown and the goal of treatment is to stop disease progression and to reduce associated symptoms.
CONFLICTS OF INTEREST
The authors report no conflicts of interest.

AUTHOR CONTRIBUTIONS
Dr. Alkhayal was first one to examine the patient and doing biopsy and he wrote the introduction and abstract in addition to literature review. Dr. Hind took the photograph with dermatoscope and she did Literature review plus auditing the case. Dr almubark and alsudairy wrote the conclusion and review the case.

ETHICAL APPROVAL
Patient-informed consent was signed by the patient.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available without restriction. All data are included within the manuscript.

ORCID
Fares A. Alkhayal © https://orcid.org/0000-0002-4735-9796

REFERENCES
1. Assouly P, Reygagne P. Lichen planopilaris: update on diagnosis and treatment. Semin Cutan Med Surg. 2009;28(1):3-10. 10.1016/j.sder.2008.12.006
2. Soares VC, Mulini-Brenner F, Souza TE. Lichen planopilaris epidemiology: a retrospective study of 80 cases. An Bras Dermatol. 2015;90(5):666-670.
3. Divine J, Rudnick EW, Lien M. Graham-Little-Piccardi-Lassueuer syndrome. Cutis. 2019;103(5):E8-E11.
4. Ghafoor R, Khoso BK, Anwar MI, Hashmi SF. Graham-Little-Piccardi-Lassueuer syndrome: a rare case report and review of literature. J Pak Assoc Dermatol. 2016;25(4):327-330.
5. Karnik P, Tekeste Z, McCormick TS, et al. Hair follicle stem cell-specific PPARy deletion causes scarring alopecia. J Invest Dermatol. 2009;129(5):1243-1257.
6. Yang CC, Khanna T, Sallee B, Christiano AM, Borden LA. Tofacitinib for the treatment of lichen planopilaris: a case series. Dermatol Ther. 2018;31(6):e12656.
7. Rácz E, Gho C, Moorman PW, Noordhoek Hegt V, Neumann HA. Treatment of frontal fibrosing alopecia and lichen planopilaris: a systematic review. J Eur Acad Dermatol Venereol. 2013;27(12):1461-1470.
8. Baibergenova A, Walsh S. Use of pioglitazone in patients with lichen planopilaris. J Cutan Med Surg. 2012;16(2):97-100.
9. Chiang C, Sah D, Cho BK, Ochoa BE, Price VH. Hydroxychloroquine and lichen planopilaris: efficacy and introduction of Lichen Planopilaris Activity Index scoring system. J Am Acad Dermatol. 2010;62(3):387-392.
10. Navarini AA, Kolios AG, Prinz-Vavricka BM, Haug S. Low-dose excimer 308-nm laser for treatment of lichen planopilaris. Arch Dermatol. 2011;147(11):1325-1326.
11. Strazzulla LC, Avila L, Lo SK, Shapiro J. Novel treatment using low-dose naltrexone for lichen planopilaris. J Drugs Dermatol. 2017;16(11):1140.

How to cite this article: Alkhayal FA, Alsudairy F, al Mubarak L, Almohanna HM. Graham-Little Piccardi Lassueuer syndrome and review of the literature. Clin Case Rep. 2021;9:e04761. https://doi.org/10.1002/ccr3.4761